Global RNA Market Dominated by North America with 94% Share in 2035: Asia-Pacific Shows Rapid Growth Potential - Latest Insights and Investments Unveiled

News provided by

Oct 12, 2023, 10:15 ET

DUBLIN, Oct. 12, 2023 /PRNewswire/ -- The "RNA Therapeutics Market and RNA Vaccines Market by Type of Modality, Type of Molecule, Therapeutic Areas, Route of Administration, Key Geographical Regions (North America, Europe and Asia-Pacific) and Leading Players: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.

The global RNA Vaccines and RNA Therapeutics market is projected to experience substantial growth, with an estimated worth of over USD 1.1 billion by 2035 and a compounded annual growth rate (CAGR) of 50% during the forecast period from 2026 to 2035.

RNA-based therapeutics have gained prominence in the healthcare industry due to their potential in protein production and gene function regulation, offering advantages in terms of therapeutic efficacy and safety compared to traditional treatment approaches.

Key Highlights and Trends:

Next Generation RNA Therapeutics and Vaccines: The market is witnessing the development of next-generation RNA therapeutics and vaccines that target diseases previously considered undruggable. These include modalities such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA). These therapies offer structural stability, expression specificity, targeted delivery, non-immunogenicity, high efficiency, and the ability to target a wide range of therapeutic areas.
Clinical Trials: Over 100 next-generation RNA therapeutics and RNA vaccines are currently approved or in various stages of development, with nearly 25% in clinical trials. A significant portion of these candidates focuses on infectious diseases (40%) and oncological disorders (32%). High research efforts and clinical trials in this domain indicate substantial growth potential.
Self-Amplifying mRNA Vaccines: Self-amplifying mRNA (saRNA) vaccines have gained attention, with advantages over first-generation mRNA vaccines. These saRNA vaccines offer enhanced stability, low concentration administration, and prolonged therapeutic effects, making them a potential alternative to traditional RNA-based approaches.
tRNA Therapeutics: Transfer RNA (tRNA) therapies are being explored by companies like Alltrna and ReCode Therapeutics. These therapies involve engineering tRNA to correct gene codes and regulate gene expression. Although still in early stages of development, these therapies hold promise for conditions such as Cystic Fibrosis, Duchenne Muscular Dystrophy, and Pulmonary Sarcoidosis.
Circular RNA Therapeutics: Circular RNA therapies have attracted interest due to their stability. Start-ups and funding activity in this field have surged, with companies like Chimerna Therapeutics, Esperovax, and Orna Therapeutics making significant strides. Collaborations and partnerships are driving the development of circular RNA therapies.
North America Dominance: North America leads the market, with approximately 94% of the market share projected for 2035. However, Asia-Pacific is expected to experience faster growth during the forecast period.
Stakeholder Engagement: Many companies are partnering to advance research and development in next-generation RNA therapeutics and vaccines. Several strategic partnerships have been established, with over 22% focused on research and development agreements.
Investment and Funding: The market has attracted substantial investments, with over $2.9 billion raised or invested in RNA therapeutics and RNA vaccines development since 2019. This indicates strong interest and financial support from stakeholders.
Recent Developments: Notable recent developments include collaborations between Tevard Biosciences and Vertex Pharmaceuticals for tRNA therapies, Esperovax and Gingko Bioworks for circular RNA therapeutics, and HDT Bio's technology utilization agreement with the Pan African Cancer Research Institute (PACRI) for self-amplifying RNA vaccines and therapeutics.

The rapid pace of innovation, encouraging clinical trial results, accelerated approvals, and the continued efforts of both industry and non-industry players are expected to drive significant growth in the next-generation RNA vaccines and RNA therapeutics market during the forecast period.

Key Topics Covered:

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE

7. TECHNOLOGY LANDSCAPE

8. DRUG PROFILES

9. CLINICAL TRIAL ANALYSIS

10. PATENT ANALYSIS

11. PARTNERSHIPS AND COLLABORATIONS

12. FUNDING AND INVESTMENT ANALYSIS

13. BIG PHARMA INITIATIVES

14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035

15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY

16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE

17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA

18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS

20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS

Companies Mentioned

4SR Biosciences
8VC
Alexandria Real Estate Equities
Alltrna
AlphaVax
aMoon
Apple Tree Partners
Arcturus Therapeutics
Aspire Capital
AstraZeneca
Atlas Special Opportunities
aTyr Pharma
Aurora Vaccines
Avidity Partners
AyurMaya Capital Management Fund
BeiGene
MPM BioImpact
BioNTech
Camford Capital
Catalent
Charles River
Chimerna Therapeutics
Chimeron Bio
Circio
Circularis
Coalition for Epidemic Preparedness Innovations (CEPI)
Colt Ventures
Cowen Healthcare Investments
Creative Biolabs
CSL Behring
CSL Seqirus
CureVac
Curia
Dualsystems Biotech
Duke-NUS Medical School
EcoR1 Capital
Eli Lilly
Elixirgen Therapeutics
Epidarex
Esperovax
F2 Ventures
Flagship Pioneering
FPV Ventures
Frazier Life Sciences
Friends of FSH Research
FUJIFILM
FUJIFILM Diosynth Biotechnologies
Genevant Sciences
George Mason University
Gilead Sciences
Ginkgo Bioworks
GlaxoSmithKline
Gritstone bio
hC Bioscience
HDT Bio
Hercules Capital
ImmunityBio
Imperial College London
Israeli Ministry of Health
Japanese Ministry of Economy, Trade and Industry (METI)
K2 HealthVentures
Konishiyasu
KYORIN Pharmaceutical
Laronde
Leaps by Bayer
Levatio Therapeutics
Maryland Industrial Partnerships
thisMerck
Michigan Rise
MiNA Therapeutics
miRecule
Miyako Capital
MPM Capital
MSA Capital
MUFG Bank
National Cancer Institute (NCI)
National Institutes of Health
Nobelpharma
Oncorus
OrbiMed
Orbital Therapeutics
Orna Therapeutics
Pan African Cancer Research Institute (PACRI)
Panacea Venture
Perceptive Advisors
Pfizer
Playground Global
Precision NanoSystems
Quanchuang Capital
Recipharm
ReCode Therapeutics
Redmile Group
Replicate Bioscience
Ring Code Biotech
Sanofi
Servier
ShapeTX
Silicon Valley Bank
Simnova
SK Impact Fund
Sojitz
Solve FSHD
Strand Therapeutics
SYTE.bio
Taiho Ventures
Takeda Ventures
Tevard Biosciences
Biomedical Advanced Research and Development Authority (BARDA)
Coalition for Epidemic Preparedness Innovations (CEPI)
National Institute of Allergy and Infectious Diseases
The National University Cancer Institute, Singapore (NCIS)
University of Nebraska Medical Center
The University of Texas Medical Branch (UTMB)
Therorna
Transine Therapeutics
TriLink BioTechnologies
University of Antwerp
UZ Gent
VaxEquity
Vertex Pharmaceuticals
Vida Ventures
Vingroup
VLP Therapeutics
Ziphius Vaccines
Zogenix (Acquired by UCB)
Zoic Capital

For more information about this report visit https://www.researchandmarkets.com/r/6d3f5e

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets